This article is more than 5 years old. Information may no longer be current.

Anti-VEGF effective in wet AMD, diabetic retinopathy

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

SEATTLE — Patients diagnosed with both neovascular age-related macular degeneration and diabetic retinopathy who received intravitreal injections showed stabilization in best-corrected visual acuity and reduction in central macular thickness, according to a poster presented here.

“Long-term analysis of intravitreal anti-VEGF therapy for eyes with both neovascular AMD and DR showed stabilization of BCVA and a reduction in CMT, along with stable or improved DR throughout follow-up,” Lea Querques, MD, said at the Association for Research in Vision and Ophthalmology meeting.

The retrospective study enrolled 41 eyes of 38 patients from four high volume referral centers who had concomitant wet AMD and diabetic retinopathy. Thirteen eyes were administered a mean number of 5.7 injections of Avastin (bevacizumab, Genentech), 35 eyes were administered a mean number of 6.6 injections of Lucentis (ranibizumab, Genentech), eight eyes were administered a mean number of 6.1 injections of Eylea (aflibercept, Regeneron) and one eye was administered 7 injections of Macugen (pegaptanib, Bausch + Lomb).

Median follow-up was 28 months.

Mean BCVA was 0.5 logMAR at baseline and 0.6 logMAR at last follow-up visit (P = .26). Mean central macular thickness was 408 m at baseline and 335 m at the last follow-up visit (P = .032).

No adverse events were reported.

At baseline, 21 eyes were graded on the International Clinical Diabetic Retinopathy Disease Severity Scale as mild nonproliferative diabetic retinopathy (NPDR), 15 eyes as were graded as moderate NPDR, and three eyes were graded as severe NPDR. Two eyes were graded as proliferative diabetic retinopathy that was inactive due to panretinal photocoagulation, Querques said.

During follow-up, one eye was graded as moderate NPDR and one eye as severe NPDR, but it was inactivated due to photocoagulation. – by Nhu Te

Reference:

Querques L. Long-term outcomes of intravitreal anti-VEGF therapy in eyes with both neovascular age-related macular degeneration and diabetic retinopathy. Presented at: ARVO; May 1-5, 2016; Seattle, Washington.

Disclosure: Querques reported she has no relevant financial disclosures.